Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Praxis Precision Medicines (PRAX) over the last 5 years, with Dec 2024 value amounting to $308,000.

  • Praxis Precision Medicines' Gains from Investment Securities rose 5100.00% to $52,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 814.74%. This contributed to the annual value of $308,000 for FY2024, which is 124.82% up from last year.
  • According to the latest figures from FY2024, Praxis Precision Medicines' Gains from Investment Securities is $308,000, which was up 124.82% from $137,000 recorded in FY2023.
  • Over the past 5 years, Praxis Precision Medicines' Gains from Investment Securities peaked at $4.1 million during FY2021, and registered a low of $137,000 during FY2023.
  • In the last 3 years, Praxis Precision Medicines' Gains from Investment Securities had a median value of $260,000 in 2022 and averaged $235,000.
  • As far as peak fluctuations go, Praxis Precision Medicines' Gains from Investment Securities tumbled by 93.61% in 2022, and later surged by 124.82% in 2024.
  • Praxis Precision Medicines' Gains from Investment Securities (Yearly) stood at $4.1 million in 2021, then slumped by 93.61% to $260,000 in 2022, then slumped by 47.31% to $137,000 in 2023, then surged by 124.82% to $308,000 in 2024.